 Connection
Mark Nehler to Peripheral Arterial Disease
This is a "connection" page, showing publications Mark Nehler has written about Peripheral Arterial Disease.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.347 |
|
|
|
-
Govsyeyev N, Malgor RD, Hoffman C, Harroun N, Sturman E, Al-Musawi M, Malgor EA, Jacobs DL, Nehler M. A systematic review and meta-analysis of outcomes after acute limb ischemia in patients with cancer. J Vasc Surg. 2021 09; 74(3):1033-1040.e1.
Score: 0.455
-
Long CA, Mulder H, Fowkes FGR, Baumgartner I, Berger JS, Katona BG, Mahaffey KW, Norgren L, Blomster JI, Rockhold FW, Hiatt WR, Patel MR, Jones WS, Nehler MR. Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. Circ Cardiovasc Qual Outcomes. 2020 07; 13(7):e006399.
Score: 0.430
-
Nehler MR, Duval S, Diao L, Annex BH, Hiatt WR, Rogers K, Zakharyan A, Hirsch AT. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg. 2014 Sep; 60(3):686-95.e2.
Score: 0.281
-
Canonico ME, Low Wang CC, Hsia J, Debus ES, Nehler MR, Patel MR, Anand SS, Ycas J, Capell WH, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs R, Bonaca MP. Low-Dose Rivaroxaban Plus Aspirin in?Fragile Patients After Lower Extremity?Revascularization. J Am Coll Cardiol. 2024 Aug 27; 84(9):801-811.
Score: 0.143
-
Hess CN, Daffron A, Nehler MR, Morrison JT, Buchanan CE, Szarek M, Anderson VE, Cannon CP, Hsia J, Saseen JJ, Bonaca MP. Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2024 Jun 25; 83(25):2658-2670.
Score: 0.142
-
Morrison JT, Canonico ME, Anand SS, Patel MR, Debus ES, Nehler MR, Hess CN, Hsia J, Capell WH, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs RM, Bonaca MP. Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD. Circulation. 2024 May 07; 149(19):1536-1539.
Score: 0.140
-
Rogers RK, Herold J, Govsyeyev N, Iezzi R, Morrison J, Hogan SE, Nehler M, Bricker R, Andring B, Bergmark B, Cavender M, Malgor E, Jacobs D, Young MN, Capell W, Ycas JW, Anand SS, Berkowitz SD, Debus ES, Haskell LP, Muehlhofer E, Patel MR, Hess CN, Bauersachs RM, Anderson V, Bonaca MP. Methods, design, and initial results of an angiographic core lab from VOYAGER-PAD. Vasc Med. 2024 04; 29(2):143-152.
Score: 0.139
-
Hogan SE, Holland M, Burke J, Johnson P, McNeal D, Cicutto L, Nehler M, Peterson PN. Retrospective Review of Directional Atherectomy and Drug-Coated Balloon Use in a PAD Safety-Net Population. J Invasive Cardiol. 2023 04; 35(4):E205-E216.
Score: 0.130
-
Govsyeyev N, Nehler M, Conte MS, Debus S, Chung J, Dorigo W, Gudz I, Krievins D, Mills J, Moll F, Norgren L, Piffaretti G, Powell R, Szalay D, Sillesen H, Wohlauer M, Szarek M, Bauersachs RM, Anand SS, Patel MR, Capell WH, Jaeger N, Hess CN, Muehlhofer E, Haskell LP, Berkowitz SD, Bonaca MP. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. J Vasc Surg. 2023 04; 77(4):1107-1118.e2.
Score: 0.127
-
Bonaca MP, Szarek M, Debus ES, Nehler MR, Patel MR, Anand SS, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM. Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD. Clin Cardiol. 2022 Dec; 45(12):1143-1146.
Score: 0.126
-
Hess CN, Baumgartner I, Anand SS, Nehler MR, Patel MR, Debus ES, Szarek M, Capell W, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM, Bonaca MP, Hsia J. Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. J Am Heart Assoc. 2022 06 21; 11(12):e024655.
Score: 0.123
-
Hess CN, Szarek M, Anand SS, Bauersachs RM, Patel MR, Debus ES, Nehler MR, Capell WH, Beckman JA, Piazza G, Henkin S, Bura-Rivi?re A, Lawall H, Roztocil K, Hsia J, Muehlhofer E, Berkowitz SD, Haskell LP, Bonaca MP. Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. JAMA Netw Open. 2022 06 01; 5(6):e2215580.
Score: 0.123
-
Anand SS, Hiatt W, Dyal L, Bauersachs R, Berkowitz SD, Branch KRH, Debus S, Fox KAA, Liang Y, Muehlhofer E, Nehler M, Haskell LP, Patel M, Szarek M, Yusuf S, Eikelboom J, Bonaca MP. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. Eur J Prev Cardiol. 2022 05 05; 29(5):e181-e189.
Score: 0.122
-
Hogan SE, Nehler MR, Anand S, Patel MR, Debus S, Jackson MT, Buchanan C, King RW, Hess C, Muehlhofer E, Haskell LP, Bauersachs RM, Berkowitz SD, Hsia J, Bonaca MP. Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. Vasc Med. 2022 08; 27(4):343-349.
Score: 0.122
-
Berkowitz SD, Bauersachs RM, Szarek M, Nehler MR, Debus ES, Patel MR, Anand SS, Capell WH, Hess CN, Hsia J, Leeper NJ, Brasil D, M?ty?s L, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Bonaca MP. Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. J Thromb Haemost. 2022 05; 20(5):1193-1205.
Score: 0.121
-
Hess CN, Patel MR, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Fanelli F, Yeh RW, Secemsky EA, Beckman JA, Mauri L, Govsyeyev N, Capell WH, Brackin T, Berkowitz SD, Muehlhofer E, Haskell LP, Hiatt WR, Bonaca MP. Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery?Revascularization: Insights From VOYAGER PAD. J Am Coll Cardiol. 2021 11 02; 78(18):1768-1778.
Score: 0.118
-
Krantz MJ, Debus SE, Hsia J, Patel MR, Anand SS, Nehler MR, Hess CN, Capell WH, Bracken T, Szarek M, M?ty?s L, Krievins DK, Nault P, Stefanov S, Haskell LP, Berkowitz SD, Muehlhofer E, Hiatt WR, Bauersachs RM, Bonaca MP. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. Eur Heart J. 2021 10 14; 42(39):4040-4048.
Score: 0.117
-
Govsyeyev N, Nehler MR, Low Wang CC, Kavanagh S, Hiatt WR, Long C, Jones WS, Fowkes FGR, Berger JS, Baumgartner I, Patel MR, Goodney PP, Beckman JA, Katona BG, Mahaffey KW, Blomster J, Norgren L, Bonaca MP. Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. J Vasc Surg. 2022 02; 75(2):660-670.e3.
Score: 0.117
-
Debus ES, Nehler MR, Govsyeyev N, Bauersachs RM, Anand SS, Patel MR, Fanelli F, Capell WH, Brackin T, Hinterreiter F, Krievins D, Nault P, Piffaretti G, Svetlikov A, Jaeger N, Hess CN, Sillesen HH, Conte M, Mills J, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR, Bonaca MP. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation. 2021 10 05; 144(14):1104-1116.
Score: 0.116
-
Bauersachs RM, Szarek M, Brodmann M, Gudz I, Debus ES, Nehler MR, Anand SS, Patel MR, Hess CN, Capell WH, Rogers K, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR, Bonaca MP. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD?Trial. J Am Coll Cardiol. 2021 07 27; 78(4):317-326.
Score: 0.114
-
Weissler EH, Jones WS, Desormais I, Debus S, Mazzolai L, Espinola-Klein C, Nikol S, Nehler M, Sillesen H, Aboyans V, Patel MR. Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. Atherosclerosis. 2020 12; 315:10-17.
Score: 0.110
-
Hiatt WR, Bonaca MP, Patel MR, Nehler MR, Debus ES, Anand SS, Capell WH, Brackin T, Jaeger N, Hess CN, Pap AF, Berkowitz SD, Muehlhofer E, Haskell L, Brasil D, Madaric J, Sillesen H, Szalay D, Bauersachs R. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. Circulation. 2020 12 08; 142(23):2219-2230.
Score: 0.110
-
Debus ES, Nehler MR. The Voyager PAD Trial - New Path for Post-revascularisation PAD Patients. Eur J Vasc Endovasc Surg. 2020 May; 59(5):699-700.
Score: 0.106
-
Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, M?ty?s L, Krievins DK, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020 05 21; 382(21):1994-2004.
Score: 0.106
-
Govsyeyev N, Nehler MR, Hiatt WR, Bonaca MP. Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. Curr Cardiol Rep. 2020 Jan 29; 22(3):13.
Score: 0.104
-
Bauersachs R, Debus S, Nehler M, Huelsebeck M, Balradj J, Bowrin K, Briere JB. A Targeted Literature Review of the Disease Burden in Patients With Symptomatic Peripheral Artery Disease. Angiology. 2020 Apr; 71(4):303-314.
Score: 0.104
-
Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, Berkowitz SD, Debus ES, Fanelli F, Haskell L, Patel MR, Bauersachs R, Hiatt WR. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018 05; 199:83-91.
Score: 0.091
-
Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, M?ller-H?lsbeck S, Nehler MR, Benenati JF, Scheinert D. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015 Jul 09; 373(2):145-53.
Score: 0.076
-
Jaff MR, Rosenfield K, Scheinert D, Rocha-Singh K, Benenati J, Nehler M, White CJ. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial. Am Heart J. 2015 Apr; 169(4):479-85.
Score: 0.073
-
Reppert AE, Jazaeri O, Babu A, Greenberg JI, Deluka E, Nehler MR, Reece TB. Minimal thoracotomy thoracic bifemoral bypass in the endovascular era. Ann Vasc Surg. 2014 Aug; 28(6):1420-5.
Score: 0.070
-
Mays RJ, Casserly IP, Kohrt WM, Ho PM, Hiatt WR, Nehler MR, Regensteiner JG. Assessment of functional status and quality of life in claudication. J Vasc Surg. 2011 May; 53(5):1410-21.
Score: 0.056
-
Hogan SE, Debus ES, Nehler MR, Patel MR, Anand SS, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs RM, Bonaca MP. Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD. Circulation. 2024 02 20; 149(8):635-637.
Score: 0.035
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|